Goldman Sachs Upgrades BioNTech, Citing Oncology Pipeline Strength

In a significant shift of outlook, Goldman Sachs has revised its rating for BioNTech SE from 'Neutral' to 'Buy'. The investment bank simultaneously raised its price target substantially, moving it from $115 to $142 per share. According to analysts, the market is currently undervaluing the company's potential in cancer therapeutics, focusing excessively on declining COVID-19 vaccine revenue instead.

The upgrade is rooted in what Goldman describes as a "unique risk-reward profile," largely supported by BioNTech's substantial cash reserves and a diversified development pipeline. A key element of the bullish stance is the timeline: 2026 is identified as a "catalyst-rich year," during which critical clinical trial results are expected to set the stage for the firm's future valuation.

This perspective aligns with the strategic roadmap BioNTech recently outlined at the J.P. Morgan Healthcare Conference. The company's transition into a multi-product oncology-focused entity is backed by concrete milestones:

Should investors sell immediately? Or is it worth buying BioNTech?

• A total of 15 active Phase 3 trials are slated by the end of 2026.
• Seven data readouts from late-stage development programs are anticipated before the close of this year.
• The long-term strategy envisions at least 17 late-stage clinical results by 2030, solidifying its transformation.

Financially, BioNTech is well-positioned to fund this ambitious agenda independently. As of the end of December 2025, the company held €17.2 billion in liquid assets and securities, providing ample resources to advance its pipeline without seeking external financing.

Consolidation and Competitive Positioning

Further strengthening its position, BioNTech has finalized the acquisition of CureVac. The competitor's shares were delisted from the stock exchange on January 16, 2026. This move not only secures valuable intellectual property for BioNTech but also removes a direct rival in the mRNA technology space.

The combined effect of a prominent analyst upgrade and clear strategic execution is currently benefiting the equity. Investors are increasingly pricing in the long-term potential of the oncology portfolio, rather than concentrating solely on the anticipated drop in pandemic-related sales. The coming months will be crucial in determining whether the clinical data can meet the heightened expectations now placed on the company.